Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xing Yin

Showing results (371-380 of 374) with videos related to

Pageof 38
Sort By:
You have reached the last page of results.This site can display upto 374 results.
Zhonghua Xin Xue Guan Bing Za Zhi|September 29, 2005
[Survey on blood pressure and serum lipids in Hei Yi Zhuang Chinese living in Guangxi]Rui-xing Yin, Shang-ling Pan, Wei-xiong Lin, et al.
Cancer Pathogenesis and Therapy|July 23, 2025
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trialYuankai Shi, Minghong Bi, Qingshan Li, et al.
Cancer Research|October 28, 2025
Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary NodulesHuaichao Luo, Wei Guo, Xinyu Luan, et al.
Scientific Data|April 19, 2019
Data from the Human Penguin Project, a cross-national dataset testing social thermoregulation principlesChuan-Peng Hu, Ji-Xing Yin, Siegwart Lindenberg, et al.
Pageof 38

Showing results (371-380 of 374) with videos related to

Sort By:
Pageof 38
You have reached the last page of results.This site can display upto 374 results.
Zhonghua Xin Xue Guan Bing Za Zhi|September 29, 2005
[Survey on blood pressure and serum lipids in Hei Yi Zhuang Chinese living in Guangxi]Rui-xing Yin, Shang-ling Pan, Wei-xiong Lin, et al.
Cancer Pathogenesis and Therapy|July 23, 2025
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trialYuankai Shi, Minghong Bi, Qingshan Li, et al.
Cancer Research|October 28, 2025
Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary NodulesHuaichao Luo, Wei Guo, Xinyu Luan, et al.
Scientific Data|April 19, 2019
Data from the Human Penguin Project, a cross-national dataset testing social thermoregulation principlesChuan-Peng Hu, Ji-Xing Yin, Siegwart Lindenberg, et al.
Pageof 38